Is there a dose that converts semaglutide to tirzepatide?

What the labels say about switching
ProductStartMaintenance or ceiling
Ozempic0.25 mg once weekly for 4 weeks3Up to 2 mg once weekly if more glycemic control is needed3
Wegovy0.25 mg once weekly for 4 weeks4For weight reduction in adults, 1.7 mg or 2.4 mg once weekly; 7.2 mg once weekly after at least 4 weeks on 2.4 mg if more weight reduction is clinically indicated4
Mounjaro2.5 mg once weekly5Up to 15 mg once weekly in adults, 10 mg once weekly in pediatric patients 10 years and older with type 2 diabetes5
Zepbound2.5 mg once weekly for 4 weeks, not a maintenance dose65 mg, 10 mg or 15 mg once weekly; 10 mg or 15 mg for OSA6

None of the Mounjaro, Zepbound, Ozempic or Wegovy labels gives a semaglutide to tirzepatide conversion; a 2026 model-based analysis of trials in type 2 diabetes (Builes-Montaño and colleagues) found a 99.4% probability that semaglutide 2.4 mg and tirzepatide 10 mg are equivalent for weight loss, while a Pharmaceutical Journal article says there is no validated dose equivalence.12

What the labels say about switching

The Mounjaro, Zepbound, Ozempic and Wegovy labels (GLP-1 drugs) have no switching section for semaglutide and tirzepatide.

The table is set at the top of the page

Trials that compared or switched these drugs

SURMOUNT-5 (Aronne and colleagues, 2025; 751 participants) compared the two drugs head to head; Fukaishi and Ishibashi (2025) switched eleven people from oral semaglutide to tirzepatide.78

TrialDose and schedulePeople
SURMOUNT-5Maximum tolerated tirzepatide (10 mg or 15 mg) against semaglutide (1.7 mg or 2.4 mg), once weekly for 72 weeks7751 adults with obesity but without type 2 diabetes7
Single-clinic study, JapanOral semaglutide 14 mg (nine people) or 7 mg (two) to tirzepatide 2.5 mg, then 5 mg after 4 weeks, for 3 months8Eleven patients with type 2 diabetes, switched for insufficient weight reduction8

What a journal article, a review and a model say

A Pharmaceutical Journal article by Sehar Shahid, a clinical trainer for Eli Lilly (first published in December 2025 and updated on 24 July 2026), says there is no NICE or MHRA guidance on switching between the two and no validated dose equivalence.2 It advises restarting semaglutide at 0.25 mg weekly whatever the previous tirzepatide dose, while a 2.4 mg semaglutide dose can go straight to the 25 mg tablet.2 A 2026 model-based analysis by Builes-Montaño and colleagues (two of three authors at Novo Nordisk) used 48 arms (16,524 participants) from separate phase III type 2 diabetes trials; with a margin of 2 points, it found 99.4% probability that semaglutide 2.4 mg and tirzepatide 10 mg are equivalent for weight loss and 94.8% for 7.2 mg and 15 mg, and found lower semaglutide doses not equivalent to higher tirzepatide doses.1

Semaglutide tablets and injections

For adults on the 2.4 mg injection for cardiovascular risk or weight reduction, the Wegovy label starts 25 mg tablets one week after it is stopped.4 It starts the 2.4 mg injection once weekly the day after 25 mg tablets once daily are stopped, and says to consider 1.7 mg for patients who do not tolerate the tablets.4 The Rybelsus label starts 7 mg or 14 mg tablets once daily one week after the 0.5 mg Ozempic injection is stopped.9

Retatrutide: regulators, trials and switching

The TGA says retatrutide is still in clinical trials and not approved by it or any comparable regulator.10 The FDA says it cannot be used in compounding under federal law.11

TrialDose and schedulePeople
Phase 2 obesity trial (Jastreboff, 2023)1 mg, 4 mg (starting at 2 or 4 mg), 8 mg (starting at 2 or 4 mg) or 12 mg (starting at 2 mg), or placebo, once weekly for 48 weeks12338 adults12

No retatrutide dose for people coming off tirzepatide or semaglutide, nor an equivalence from tirzepatide to retatrutide, turned up in PubMed, Europe PMC or ClinicalTrials.gov.

In Milligram's app logs, of the people who logged retatrutide, 21% set up 2 mg as a first dose and 18% set up 1 mg.16

How long each drug stays in the body

The tirzepatide label gives a half-life of approximately 5 days.5 The Ozempic label gives semaglutide a half-life of approximately 1 week and says it stays in the circulation for about 5 weeks after the last dose.3 A 2026 review of a first-in-human single-ascending-dose study (0.1 to 6 mg, 45 healthy participants) reports a geometric mean terminal half-life of 134 to 165 hours, about 6 days, for retatrutide.13 No label or trial gives a washout or overlap interval for moving from tirzepatide to retatrutide, and the half-lives above are not a switching rule.

Why the same dose is different units

The FDA says compounded semaglutide instructions in units can confuse, as the volume depends on concentration (see the units and dosing guide).14 Of the people who logged tirzepatide, 12% set up 10 mg with 1 mL, which is 10 mg/mL, so 2.5 mg is 0.25 mL, or 25 units.16 The Mounjaro label's 10 mg in 2.4 mL vial (4.17 mg/mL) gives 2.5 mg as 0.6 mL,5 which on a U-100 syringe is 60 units.15

How the logged figures are counted

Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

References

  1. Diabetes Therapy. Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis (abstract). 2026. pubmed.ncbi.nlm.nih.gov
  2. The Pharmaceutical Journal (Royal Pharmaceutical Society). Switching between weight-loss medications. 2025. pharmaceutical-journal.com
  3. US FDA label via DailyMed (Novo Nordisk). OZEMPIC (semaglutide) injection: prescribing information. 2026. dailymed.nlm.nih.gov
  4. US FDA label via DailyMed (Novo Nordisk). WEGOVY (semaglutide) injection and tablets: prescribing information. 2026. dailymed.nlm.nih.gov
  5. US FDA label via DailyMed (Eli Lilly). MOUNJARO (tirzepatide) injection: prescribing information. 2026. dailymed.nlm.nih.gov
  6. US FDA label via DailyMed (Eli Lilly). ZEPBOUND (tirzepatide) injection: prescribing information. 2026. dailymed.nlm.nih.gov
  7. New England Journal of Medicine. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (abstract). 2025. pubmed.ncbi.nlm.nih.gov
  8. JMA Journal. Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes. 2025. pmc.ncbi.nlm.nih.gov
  9. US FDA label via DailyMed (Novo Nordisk). RYBELSUS (semaglutide) tablets: prescribing information. 2026. dailymed.nlm.nih.gov
  10. Therapeutic Goods Administration (Australia). TGA tests counterfeit retatrutide product following serious adverse event report. 2026. tga.gov.au
  11. US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026. fda.gov
  12. New England Journal of Medicine. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (abstract). 2023. pubmed.ncbi.nlm.nih.gov
  13. peer-reviewed narrative review (PMC). Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. 2026. pmc.ncbi.nlm.nih.gov
  14. US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. 2026. fda.gov
  15. US Food and Drug Administration (510(k) database, syringe maker's submission). FDA 510(k) K233794 clearance letter and summary: Insulin Syringe (SPM Medicare). 2024. accessdata.fda.gov
  16. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted